Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting - July 3, 2023

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting held earlier today, all resolutions were duly passed on a show of hands.

Result of Annual General Meeting

LONDON, UK / ACCESSWIRE / July 3, 2023 / Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting (“AGM”) held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions Votes for % of votes cast for Votes Against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes with-held (2)
1. To adopt the 2022 Annual Report and Accounts 187,231,295 99.86 260,529 0.14 187,491,824 16.42 4,905,675
2. To approve the Directors’ Remuneration Policy 175,511,893 91.34 16,644,001 8.66 192,155,894 16.83 241,605
3. To re-appoint Peter Redmond as Director 161,957,826 86.38 25,531,232 13.62 187,489,058 16.42 4,908,441
4. To re-appoint Alexis Sandler as Director 175,078,447 93.44 12,285,451 6.56 187,363,898 16.41 5,033,601
5. To re-appoint Dr Vladislav Sandler as Director 175,160,284 93.49 12,203,614 6.51 187,363,898 16.41 5,033,601
6. To reappoint the Company’s auditor 185,776,647 99.09 1,715,177 0.91 187,491,824 16.42 4,905,675
7. To authorise the Audit Committee to determine the auditor’s remuneration 176,309,143 94.04 11,179,915 5.96 187,489,058 16.42% 4,908,441
8. To authorise the Directors to allot equity securities 170,229,487 90.79 17,259,571 9.21 187,489,058 16.42 4,908,441
Special Resolutions Votes for % of votes cast for Votes against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes with-held (2)
9. To disapply pre-emption provisions 156,025,169 89.79 17,751,132 10.21 173,776,301 15.22 18,621,198
10. To reduce the notice period for general meetings 171,582,521 91.51 15,909,303 8.49 187,491,824 16.42 4,905,675

(1) The Company’s issued share capital (“ISC”) on 28 June 2023, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,141,999,321 ordinary shares.

(2) A ‘vote withheld’ in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Enquiries:

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/764947/Hemogenyx-Pharmaceuticals-PLC-Announces-Result-of-Annual-General-Meeting

MORE ON THIS TOPIC